KCT0002004已完成未知
A 4 week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of UL-F on allergic rhinitis
STR Biotech0 个研究点目标入组 96 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •(1) Patients who provided a signed written informed consent form
- •(2) All men and women aged between 19 and 55 years
- •(3) Patients with 2 years history of allergic rhinitis
- •(4) Visit 1&Visit 2 Nasal symptom score of the 2 type more than the score of 2 points
- •(5) Positive results of skin prick test
- •(6) Last month never received a specialty drug preion for nose symptoms
排除标准
- •(1) Currently taking medication to one or more allergic diseases
- •(2) Consumption of Antihistamine/Corticosteroid, Antacids of H2 blocker within 2 weeks before the first visit
- •(3) Subjects who consumed functional foods or oriental medicine within 2 week prior to the first visit
- •(4) Gastric disease
- •(5) Patients with asthma
- •(6) Subject who has or experienced following diseases: myocardial infarction, stroke, cardiovascular disease
- •(7) alcoholic and drug addict
- •(8) hypertension (Systolic Blood Pressure =170 mmHg OR Diastolic Blood Pressure =100 mmHg)
- •(9) Diabetes (fasting glucose level = 180 mg/dL)
- •(10) Renal dysfunction (serum creatinine = 2 X upper limit of normal range)
- •(11) Liver dysfunction (AST, ALT = 2 X upper limit of normal range)
- •(12) Pregnancy or lactation
- •(13) Subjects which in the opinion investigator could affect preclude evaluation of response
研究者
相似试验
进行中（未招募）
不适用
A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAEHereditary AngioedemaMedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003923-74-HUBioCryst Pharmaceuticals Inc24
进行中（未招募）
1 期
A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAEMedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary AngioedemaEUCTR2015-003923-74-GBBioCryst Pharmaceuticals Inc24
招募中
不适用
The Evaluation of the Efficacy and Safety of NAO on Immune functioKCT0006925Dynebio100
进行中（未招募）
不适用
A 4 week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary DiseaseEUCTR2008-000340-13-BGAstraZeneca AB130
进行中（未招募）
不适用
A 4 week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseEUCTR2008-000340-13-DKAstraZeneca AB130